Secondary reconstruction of the orbit and conjunctival sac - a case report.

The authors present a novel modification of vastus lateralis muscle free flap based orbital reconstruction in a 41-year-old patient, with a secondary defect to an injury with technical oil under high pressure. The patient underwent multiple reconstructive procedures in different medical centers with poor functional and esthetic results including simple local plasty techniques. The patient underwent simultaneous reconstruction of the soft tissues of the orbit, and conjunctival sac based on a prelaminated vastus lateralis free flap. The two-stage reconstruction of these structures is beneficial both for the patient's psychical and mental condition and for health system finances. Therefore, whenever it's possible, we should try to decrease the number of required procedures. The authors believe that their technique can significantly improve the quality of life of patients after exenteration but simultaneously they emphasize the need to carry out more procedures in order to refine it.

Inappropriate metformin prescribing in elderly type 2 diabetes mellitus (T2DM) patients.

PURPOSE: Metformin is the most commonly prescribed anti-diabetic medication. However, it is often used despite the presence of contraindications and in unlicensed indications. The main aim of this study was to evaluate the frequency of metformin use before hospitalization in spite of contraindications in patients with type 2 diabetes mellitus (T2DM) and to evaluate the prevalence of metformin - associated side effects. MATERIAL/METHODS: 558 hospitalized patients (mean age = 66.65 ± 12.73 years) with poorly controlled T2DM were enrolled. Detailed medical history including the duration of T2DM, duration of hypoglycemic agents usage prior to hospitalization and possible metformin-associated side effects was recorded. Patients were subjected to a thorough physical examination and indispensable biochemical and diagnostic research panel was performed to establish the degree of heart failure, sufficiency of the respiratory system and kidney function. RESULTS: 335 out of 558 patients were treated before hospitalization with metformin alone or in combination with other hypoglycemic agents, mostly sulfonylureas. Contraindications to metformin were found in 275 patients and despite this 120 of them were using this medication in an average dose of 1793.91 ± 701.61 mg. However, none of them reported any serious adverse effects and no significant pH changes were observed. Only three patients reported moderate dyspepsia. CONCLUSIONS: The results of this study indicate a relatively good tolerability of metformin by patients with the traditional contraindications to this drug. These findings support other authors' suggestion that indications and contraindications to metformin should be re-evaluated.

Prognostic value of S-100 immunostaining in tumour cells of non-small cell lung cancer.

S-100 protein expression is present in various malignant tissues, yet its prognostic relevance is debatable. The aim was to assess in non-small cell lung cancer (NSCLC) patients' prognostic value of S-100 protein considered alone or in relation with other variables. Tumour samples taken from 86 NSCLC patients during resection were assayed for S-100 protein expression with the use of polyclonal DAKO ZO311 antibody. S-100 expression was found in 32 cases (37%). Positive staining was not correlated with clinical characteristics including age, sex, pathology type of tumour, stage and cigarette smoking. There was a tendency for simultaneous expression of S-100 and P53 protein (p=0.06). A median survival rate for the entire group was 2.3 years (95% CI, 0.9-3.6 years). The median and 5-year survival of patients with positive staining for S-100 protein was 1.5 years and 25%, respectively, compared with 3.0 years and 35%, respectively, in the S-100 negative group (p=0.17). In the final model of a multivariate analysis, S-100 protein expression in tumour cells was associated with significantly decreased survival (p=0.005). S-100 protein expression in tumour cells seems to be an independent predictor of poor prognosis in NSCLC patients.